{"id":"https://genegraph.clinicalgenome.org/r/9df893d6-c4e7-4847-916a-e5da1df05346v1.1","type":"EvidenceStrengthAssertion","dc:description":"*FZD4* was first reported in relation to autosomal dominant familial exudative vitreoretinopathy (FEVR) in 2002 (Robitaille et al., PMID: 12172548). FEVR is characterized by abnormal development of the retinal blood vessels, leading to incomplete vascularization of the peripheral retina. Features can include retinal detachment, vascular leakage, vitreoretinal traction, macular folds, peripheral avascular zones, retinal exudates, and vision loss/blindness. FEVR is known to have a high degree of inter- and intra-familial clinical variability as well as reduced penetrance. *FZD4* is one of multiple FEVR genes, and *FZD4* is associated with the disease entity exudative vitreoretinopathy 1 (MIM# 133780). *FZD4* has also been associated with retinopathy of prematurity (ROP) (MIM# 133780, described in MacDonald et al., 2005. PMID:15733276), however FEVR and ROP have great deal of clinical overlap, and these conditions can co-occur. Studies suggest that a portion of severe ROP cases harbor disease-causing *FZD4* variants and represent cases of FEVR in the setting of prematurity (PMID: 26731204). Therefore, this curation has been performed under the disease entity FZD4-related exudative vitreoretinopathy.\n\nTwelve heterozygous variants (missense, in-frame indel, nonsense, frameshift, deletion) that have been reported in fifteen probands in seven publications (PMIDs: 12172548, 14507768, 15035989, 15223780, 15488808, 21177847, 23077402) are included in this curation. The mechanism of pathogenicity is reported to be loss of function. Given the reported variable expressivity and reduced penetrance of FEVR, probands were not excluded from the curation if they had family members who were mutation positive but asymptomatic. Three studies showing linkage of the clinical phenotypes to the *FZD4* locus in large pedigrees were available in these publications (PMID:12172548, 15035989, 21177847), and contributed to the scoring of the gene-disease relationship. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. Of note, there are limited reports of individuals with biallelic *FZD4* variants with severe FEVR (PMIDs: 18161623, 38361102) or syndromic FEVR with hearing loss and developmental delay (PMID: 35951321). In some cases, the parents are reported to have mild ocular features of FEVR (PMID: 18161623), suggesting that semidominant inheritance can occur. These biallelic cases were not included in the present curation. There is not sufficient evidence in the literature at this time to determine if autosomal recessive syndromic FEVR is a separate disease entity related to *FZD4*. \n\nThis gene-disease relationship is also supported by experimental evidence, including animal models, protein interactions, expression studies, and *in vitro* functional assays (PMIDs: 15035989, 19837032, 21177847, 27489958). *FZD4* encodes Frizzled-4 (Fz4), a receptor that plays a crucial role in the Norrin/Fz4/Lrp signaling pathway that is essential for normal vascular development. The biochemical function of Fz4 matches that of the LRP5 co-receptor, which is encoded by a gene in which biallelic and monoallelic variants have been reported to cause FEVR (PMID: 15035989). In the mouse retina, Fz4 (Frizzled4) is expressed in vascular cells (endothelial cells & mural cells), photoreceptors, and some inner retinal neurons (PMID:19837032). Mice with biallelic loss of function mutations in *Fzd4* recapitulate human patient phenotypes including abnormal retinal vasculature, impaired vision, and abnormal electroretinogram (PMIDs:15035989, 19837032). In addition, studies with *Fzd4* heterozygous mice indicate that haploinsufficiency results in abnormal retinal vasculature development (PMID: 27489958). More evidence is available in the literature, but the maximum score for experimental evidence (6 pts.) has been reached.\n\nIn summary, there is definitive evidence supporting the relationship between *FZD4* and autosomal dominant FZD4-related exudative vitreoretinopathy. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Retina GCEP on April 4th, 2024 (SOP Version 10).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/9df893d6-c4e7-4847-916a-e5da1df05346","GCISnapshot":"https://genegraph.clinicalgenome.org/r/2da74e15-54c4-405c-aa44-301f4717087d","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/2da74e15-54c4-405c-aa44-301f4717087d_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10072","date":"2025-01-04T03:52:27.198Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/2da74e15-54c4-405c-aa44-301f4717087d_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10072","date":"2024-04-04T16:00:00.000Z","role":"Approver"}],"curationReasons":["DiseaseNameUpdate"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2da74e15-54c4-405c-aa44-301f4717087d_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4dd4d9b-5660-4c1b-9585-ea60ed4e6441","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4dd4d9b-5660-4c1b-9585-ea60ed4e6441_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15488808","allele":{"id":"https://genegraph.clinicalgenome.org/r/6d2fc458-f220-4b40-b7ac-ab1f97a5b18a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012193.4(FZD4):c.1024A>G (p.Met342Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA253502"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/7e63aa50-0150-491c-9d24-650c3deab0e1","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7e63aa50-0150-491c-9d24-650c3deab0e1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23077402","allele":{"id":"https://genegraph.clinicalgenome.org/r/204f1968-e8aa-4d0c-b7a7-32b4c3e14c0a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012193.4(FZD4):c.1282_1285del (p.Asp428SerfsTer2)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351356"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/88a8845f-3286-4327-969f-07719e1bdf5a","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/88a8845f-3286-4327-969f-07719e1bdf5a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14507768","allele":{"id":"https://genegraph.clinicalgenome.org/r/c5042115-68ea-441a-a2a3-065d2e9a39cc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012193.4(FZD4):c.1250G>A (p.Arg417Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA117551"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/4c7e3954-f802-496e-a169-1930327b98ab","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4c7e3954-f802-496e-a169-1930327b98ab_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15223780","allele":{"id":"https://genegraph.clinicalgenome.org/r/50d005e3-8f4e-45e5-ab21-79d4993ae065","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012193.4(FZD4):c.1501_1502del (p.Leu501SerfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA253501"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e874c22a-c979-4ec1-a314-e8c086e1654f","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e874c22a-c979-4ec1-a314-e8c086e1654f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23077402","allele":{"id":"https://genegraph.clinicalgenome.org/r/10f003db-c784-4703-b1c5-b7bae44c74e0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012193.4(FZD4):c.1482G>A (p.Trp494Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA382011095"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/c338003f-acfe-455f-86f3-4fe078371ce6","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c338003f-acfe-455f-86f3-4fe078371ce6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15223780","allele":{"id":"https://genegraph.clinicalgenome.org/r/e5953d77-d694-4d87-aa78-e81804b902b2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012193.4(FZD4):c.1513C>T (p.Gln505Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225380341"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/dcbd30a9-97a3-48fa-9ba2-ef97304cb5b6","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dcbd30a9-97a3-48fa-9ba2-ef97304cb5b6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14507768","allele":{"id":"https://genegraph.clinicalgenome.org/r/fe20d3fd-b22f-4e51-b4d9-e86b8846270a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012193.4(FZD4):c.313A>G (p.Met105Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351365"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/610c4ca5-1812-417b-acef-6b0ce029093d","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/610c4ca5-1812-417b-acef-6b0ce029093d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15223780","allele":{"id":"https://genegraph.clinicalgenome.org/r/01cc96e4-01a7-4631-a5ec-20f26eb853c1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012193.4(FZD4):c.469A>G (p.Met157Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225381512"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/f99df0be-a4e0-4ccd-b994-e2454de2679b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f99df0be-a4e0-4ccd-b994-e2454de2679b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12172548","allele":{"id":"https://genegraph.clinicalgenome.org/r/f895dfdb-c5bf-426e-ad06-eaf35649e895","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012193.4(FZD4):c.1479_1484del (p.Met493_Trp494del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA253498"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f99df0be-a4e0-4ccd-b994-e2454de2679b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Note: variant is also referred to as M493_W494del in the paper. The variant results in reduced CAMKII autophosphorylation compared to wildtype and lack of  PKC translocation to the plasma membrane.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1026ac2d-5751-4ddd-b36c-e46156af7ea8","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1026ac2d-5751-4ddd-b36c-e46156af7ea8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12172548","allele":{"id":"https://genegraph.clinicalgenome.org/r/50d005e3-8f4e-45e5-ab21-79d4993ae065"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/1026ac2d-5751-4ddd-b36c-e46156af7ea8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Figure 4 - the variant results in reduced CAMKII autophosphorylation compared to wildtype and lack of  PKC translocation to the plasma membrane.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1707049c-fee8-43dd-9750-1097a90b9f88","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1707049c-fee8-43dd-9750-1097a90b9f88_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14507768","allele":{"id":"https://genegraph.clinicalgenome.org/r/c5042115-68ea-441a-a2a3-065d2e9a39cc"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/607f6306-a919-48de-8407-3d08764d3bce","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/607f6306-a919-48de-8407-3d08764d3bce_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15223780","allele":{"id":"https://genegraph.clinicalgenome.org/r/1b7cac73-10a4-4093-9947-91e0f0ef3b8f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012193.4(FZD4):c.1498del (p.Thr500LeufsTer13)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225380385"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/108c2fd2-896f-4ac3-a3dd-57573dea6e24","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/108c2fd2-896f-4ac3-a3dd-57573dea6e24_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15035989","allele":{"id":"https://genegraph.clinicalgenome.org/r/01cc96e4-01a7-4631-a5ec-20f26eb853c1"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/1edbdf2d-656d-41f1-b35d-7648d2a58341","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1edbdf2d-656d-41f1-b35d-7648d2a58341_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14507768","allele":{"id":"https://genegraph.clinicalgenome.org/r/56dcb73a-e14f-47c2-9250-05d9a36c6cfd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012193.4(FZD4):c.957G>A (p.Trp319Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225381022"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/7b5a9c50-fe7b-4b8e-8354-fa2822e29df2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7b5a9c50-fe7b-4b8e-8354-fa2822e29df2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21177847","allele":{"id":"https://genegraph.clinicalgenome.org/r/f491940f-3061-41b9-93ae-41ddcf8f0d89","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012193.4(FZD4):c.173A>G (p.Tyr58Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA382018357"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/7b5a9c50-fe7b-4b8e-8354-fa2822e29df2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Y58C in cell-surface assays shows impaired binding to Norrin","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/2da74e15-54c4-405c-aa44-301f4717087d_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ed885d75-f85d-4357-82ce-4aed42cc7ecc_proband_segregation","type":"FamilyCosegregation","dc:description":"2 segregations","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15223780","rdfs:label":"Toomes_13","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/ed885d75-f85d-4357-82ce-4aed42cc7ecc","type":"Family","rdfs:label":"Toomes_13","member":{"id":"https://genegraph.clinicalgenome.org/r/38328958-628c-4142-9ed2-b234f63722d9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15223780","rdfs:label":"Toomes_13_proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/e5953d77-d694-4d87-aa78-e81804b902b2"},"firstTestingMethod":"PCR","phenotypeFreeText":" temporal sector of retina with deficient vascularization associated with areas of white fibrotic preretinal tissue.","secondTestingMethod":"SSCP","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/c338003f-acfe-455f-86f3-4fe078371ce6_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":6,"phenotypePositiveAllelePositive":3,"proband":{"id":"https://genegraph.clinicalgenome.org/r/38328958-628c-4142-9ed2-b234f63722d9"}},{"id":"https://genegraph.clinicalgenome.org/r/6ab4beaa-3c16-4829-8e30-cc8809ff4840_family_segregation","type":"FamilyCosegregation","dc:description":"only 1 segregation ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14507768","rdfs:label":"Kondo_Family 4","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/6ab4beaa-3c16-4829-8e30-cc8809ff4840","type":"Family","rdfs:label":"Kondo_Family 4"},"meetsInclusionCriteria":false,"phenotypeFreeText":"Peripheral non-perfusion","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":2},{"id":"https://genegraph.clinicalgenome.org/r/1443c63f-31c7-4cb0-a765-44ded9152395_proband_segregation","type":"FamilyCosegregation","dc:description":"Per Figure 1a: Multipoint lod-score plot for markers in the 11q14.1–14.3 region in a family with FEVR. The peak lod score was at AC072050CA1 between markers D11S901 and AC018775CA1. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12172548","rdfs:label":"Robitaille Family 1","estimatedLodScore":7.53,"family":{"id":"https://genegraph.clinicalgenome.org/r/1443c63f-31c7-4cb0-a765-44ded9152395","type":"Family","rdfs:label":"Robitaille Family 1","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/b1e58d48-69b9-4618-9846-c94ee203e1a1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12172548","rdfs:label":"Robitaille1_VI:9","ageType":"AgeAtReport","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f895dfdb-c5bf-426e-ad06-eaf35649e895"},"detectionMethod":"Linkage analysis, haplotype construction, positional cloning, then analysis of the coding regions of the genes in the region of interest. Sequencing PCR-amplified fragments, and confirmed with sequence analysis in other affected relatives. ","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Linkage analysis","phenotypeFreeText":"presented with bilateral retinal detachment and\na unilateral microphthalmic eye a few weeks after birth.","phenotypes":["obo:HP_0000541","obo:HP_0011480"],"previousTesting":false,"secondTestingMethod":"PCR","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/f99df0be-a4e0-4ccd-b994-e2454de2679b_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":10,"phenotypePositiveAllelePositive":25,"proband":{"id":"https://genegraph.clinicalgenome.org/r/b1e58d48-69b9-4618-9846-c94ee203e1a1"},"publishedLodScore":13.8,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/7235eec6-c99a-4ff3-9a43-deab5d9b6a98_proband_segregation","type":"FamilyCosegregation","dc:description":"3 segregations ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14507768","rdfs:label":"Kondo Family 3","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/7235eec6-c99a-4ff3-9a43-deab5d9b6a98","type":"Family","rdfs:label":"Kondo Family 3","member":{"id":"https://genegraph.clinicalgenome.org/r/395d5aee-8392-4da0-a93a-dfe77b0d1422","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14507768","rdfs:label":"Family3_II:1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":21,"allele":{"id":"https://genegraph.clinicalgenome.org/r/c5042115-68ea-441a-a2a3-065d2e9a39cc"},"firstTestingMethod":"PCR","phenotypeFreeText":"Peripheral non-perfusion OU","phenotypes":["obo:HP_0012231","obo:HP_0007663","obo:HP_0011530"],"previousTestingDescription":"Some individuals in this paper had prior screening for NDP - unclear if this family did. ","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/88a8845f-3286-4327-969f-07719e1bdf5a_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"Peripheral non-perfusion OU","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":4,"proband":{"id":"https://genegraph.clinicalgenome.org/r/395d5aee-8392-4da0-a93a-dfe77b0d1422"}},{"id":"https://genegraph.clinicalgenome.org/r/45306138-5bad-4bf7-a8a7-819eeb3f0041_proband_segregation","type":"FamilyCosegregation","dc:description":"only 1 segregation with genotype ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14507768","rdfs:label":"Kondo_Family 1","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/45306138-5bad-4bf7-a8a7-819eeb3f0041","type":"Family","rdfs:label":"Kondo_Family 1","member":{"id":"https://genegraph.clinicalgenome.org/r/a66c3239-31ce-425f-913e-e9ed541669cb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14507768","rdfs:label":"Kondo Family 1_III:1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/fe20d3fd-b22f-4e51-b4d9-e86b8846270a"},"firstTestingMethod":"PCR","phenotypeFreeText":"Vitreous opacity/membrane OU","phenotypes":["obo:HP_0001493","obo:HP_0001147","obo:HP_0025007","obo:HP_0004327","obo:HP_0007663"],"previousTestingDescription":"Per the paper, \"Before this study, some of the participants had been genotyped with 11q13–23 markers, and screened for mutations in the NDP gene,\" however it is unclear if Family 1 was one of the families previously screened. ","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/dcbd30a9-97a3-48fa-9ba2-ef97304cb5b6_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"Peripheral non-perfusion OU","phenotypePositiveAllelePositive":2,"phenotypes":"obo:HP_0007773","proband":{"id":"https://genegraph.clinicalgenome.org/r/a66c3239-31ce-425f-913e-e9ed541669cb"}},{"id":"https://genegraph.clinicalgenome.org/r/e742c7e8-984d-4148-a07c-02c40b8a6b9a_proband_segregation","type":"FamilyCosegregation","dc:description":"Only 2 confirmed segregations","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14507768","rdfs:label":"Kondo Family 2","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/e742c7e8-984d-4148-a07c-02c40b8a6b9a","type":"Family","rdfs:label":"Kondo Family 2","member":{"id":"https://genegraph.clinicalgenome.org/r/cd6c3656-88cc-4798-aff3-3949ab27861b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14507768","rdfs:label":"Family 2_III:1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":18,"allele":{"id":"https://genegraph.clinicalgenome.org/r/c5042115-68ea-441a-a2a3-065d2e9a39cc"},"firstTestingMethod":"PCR","phenotypeFreeText":"Peripheral non-perfusion, corneal opacity in one eye","phenotypes":["obo:HP_0011530","obo:HP_0025007","obo:HP_0007663","obo:HP_0000541","obo:HP_0004327","obo:HP_0001147","obo:HP_0001493"],"previousTestingDescription":"Some individuals prescreened for NDP - unclear if this family was screened. ","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1707049c-fee8-43dd-9750-1097a90b9f88_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"proband":{"id":"https://genegraph.clinicalgenome.org/r/cd6c3656-88cc-4798-aff3-3949ab27861b"}},{"id":"https://genegraph.clinicalgenome.org/r/84eae140-d443-4f84-8067-56d79fb188d6_proband_segregation","type":"FamilyCosegregation","dc:description":"Note: there are a total of 5 affected individuals in this family. 4 were genotyped and have the variant. The 4th (deceased) is an obligate mutation carrier based on pedigree - Figure 7A ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15035989","rdfs:label":"Xu_M157V family","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/84eae140-d443-4f84-8067-56d79fb188d6","type":"Family","rdfs:label":"Xu_M157V family","member":{"id":"https://genegraph.clinicalgenome.org/r/aaf7dbf6-35fb-4b83-954c-c24ba4a3dc0b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15035989","rdfs:label":"Xu_M157V subject 05","allele":{"id":"https://genegraph.clinicalgenome.org/r/01cc96e4-01a7-4631-a5ec-20f26eb853c1"},"detectionMethod":"No specific information provided about genotyping method","phenotypes":"obo:HP_0001493","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/108c2fd2-896f-4ac3-a3dd-57573dea6e24_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":4,"phenotypes":"obo:HP_0001493","proband":{"id":"https://genegraph.clinicalgenome.org/r/aaf7dbf6-35fb-4b83-954c-c24ba4a3dc0b"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/f60bb149-ab71-4f48-b7df-1a2e17a065d0_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21177847","rdfs:label":"Family B","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/f60bb149-ab71-4f48-b7df-1a2e17a065d0","type":"Family","rdfs:label":"Family B","member":{"id":"https://genegraph.clinicalgenome.org/r/f35ba219-4ed9-49db-ad0f-52525b227a0d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21177847","rdfs:label":"III:1","allele":{"id":"https://genegraph.clinicalgenome.org/r/f491940f-3061-41b9-93ae-41ddcf8f0d89"},"detectionMethod":"FZD4 sequencing ","firstTestingMethod":"PCR","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7b5a9c50-fe7b-4b8e-8354-fa2822e29df2_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":5,"proband":{"id":"https://genegraph.clinicalgenome.org/r/f35ba219-4ed9-49db-ad0f-52525b227a0d"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/2da74e15-54c4-405c-aa44-301f4717087d_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2da74e15-54c4-405c-aa44-301f4717087d_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/005fa0d0-1f03-44ac-8eb5-58806f815926","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/727d6972-33ef-498d-a89c-cdd4a7cc92ea","type":"Finding","dc:description":"In the retina, Fz4 (Frizzled4) is expressed in vascular cells (endothelial cells & mural cells), photoreceptors, and some inner retinal neurons. Expression in retinal and vascular cells is consistent with expression in tissues relevant for disease associated with FZD4. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19837032","rdfs:label":"Fz4 expression in adult mouse retina ","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/05215b9c-277c-48f6-9447-19de197f5fc3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/afbda036-16dc-4e90-aa14-cb34e3e5da95","type":"Finding","dc:description":"high affinity of Norrin-Fz4 binding. These studies indicate that that Norrin and Fz4 function as a ligand-receptor pair. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15035989","rdfs:label":"High-Affinity Binding between Norrin and Fz4","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/63d9a966-c89b-4b4a-b0f3-8cde9c613ae3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/14d6d2fc-c7a3-4e54-91f7-3c69899beac0","type":"Finding","dc:description":"Researchers assessed ability of norrin to activate canonical Wnt pathway using a 293 cell line stably transfected with a luciferase reporter. Lrp5 and Fz4 showed low levels of reporter activation, though the combination of Lrp5 (or 6) and Fz4 showed higher activation. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15035989","rdfs:label":"Canonical Wnt pathway activation studies","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/2da74e15-54c4-405c-aa44-301f4717087d_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ea8acded-02d8-4a9c-89b9-3c4fa0ed15a9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e00d456-d9e4-4df2-8a56-1dd45cac14b6","type":"FunctionalAlteration","dc:description":"Defects in formation of capillary-like structures ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19837032","rdfs:label":"Retinal endothelial cell culture"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d4f57fb0-181a-4337-aeb6-a610f72370fb","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57d983cd-b894-4e23-a660-f1f240c06123","type":"FunctionalAlteration","dc:description":"\"hFz4 variants fail to induce luciferase activity in STF cells in response to hNorrin-rho\"","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15035989","rdfs:label":"Luciferase Assays"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/303bde19-5e13-447c-926f-53f1262ec854","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97d14e5b-e625-4a5e-ba94-f491290d073a","type":"FunctionalAlteration","dc:description":" FZD4 showed impaired binding to Norrin with Y58C and C204R mutants","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21177847","rdfs:label":"Cell-surface binding assays"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/2da74e15-54c4-405c-aa44-301f4717087d_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/75389397-d1fa-449b-afbe-39b49c5db75b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/587d7dfc-dfd7-4f11-8a66-f89119ddc8e4","type":"Finding","dc:description":"Main feature of FEVR is retinal vascular defect, and this is seen in the fz4-/-null mouse. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15035989","rdfs:label":"fz4−/− mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ada01f84-70dd-43c6-b65a-ea4d474b8e2b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bdca1f96-7fce-426f-8959-3f211f438799","type":"Finding","dc:description":"Fzd4+/- indicate that haplo-insufficiency results in abnormal retinal vasculature development, seen as early as P12. This is consistent with abnormal retinal vasculature in humans with heterozygous mutations from early in life ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27489958","rdfs:label":"Fzd4+/- mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3df626a6-628a-4fcd-86a7-807e18d71c16","type":"EvidenceLine","dc:description":"Down-scoring as I've scored another paper with a null mouse. This one adds information about vision defect in the mice looking at ERG. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fc6b6798-7746-4cb9-9ab3-ae094676a21a","type":"Finding","dc:description":"Sparse vascular coverage and reduced vascular growth in the null mouse retina is consistent with abnormal vasculature in affected people with FEVR. In addition, ERG recordings in the null mice indicate visual defects, which is consistent with visual loss that can be seen in patients. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19837032","rdfs:label":"Fz4−/− mouse retina and vision evaluation","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":9669,"specifiedBy":"GeneValidityCriteria10","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/uAjv2NUZlGY","type":"GeneValidityProposition","disease":"obo:MONDO_1040041","gene":"hgnc:4042","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_2da74e15-54c4-405c-aa44-301f4717087d-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}